PCRX is set to sell its iovera franchise to ZBH in a deal worth up to $140M as it sharpens focus on

HC Wainwright & Co. analyst Douglas Tsao reiterates Pacira BioSciences (NASDAQ:PCRX) with a B

-- Expands Patient Access to Non-Opioid Postsurgical Pain Management Across Outpatient Settings -- B

-- Expands Patient Access to Non-Opioid Postsurgical Pain Management  Across Outpatient Settings -- 

Pacira BioSciences, Inc. (Nasdaq: PCRX), the industry leader in its commitment to deliver innovative

-- Pacira to receive up to $140 million with $70 million upfront and up to an additional $70 million

Findings presented at ISPOR 2026 showed lower opioid consumption, reduced healthcare costs, and fewe

RBC Capital analyst Douglas Miehm maintains Pacira BioSciences (NASDAQ:PCRX) with a Sector Perfor

Needham analyst Serge Belanger maintains Pacira BioSciences (NASDAQ:PCRX) with a Buy and raises t

Pacira BioSciences, Inc.___________________________ Summary of 2026 Financial Guidance(dollars in mi

Pacira BioSciences (NASDAQ:PCRX) reported quarterly earnings of $0.60 per share which beat the analy

The data were presented at the Annual Regional Anesthesiology and Acute Pain Medicine Meeting, hoste

Pacira BioSciences, Inc. (NASDAQ: PCRX), the industry leader in its commitment to deliver innovative

Barclays analyst Glen Santangelo maintains Pacira BioSciences (NASDAQ:PCRX) with a Equal-Weight a

U.S. stock futures rise, Absci falls pre-market on worse-than-expected sales. Other stocks declining

Activist investor DOMA nominates three directors to Pacira's board, citing weak oversight, misse

Pacira BioSciences, Inc. (NASDAQ:PCRX), the industry leader in its commitment to deliver innovative,

Pacira's Stock is Down 56% Over the Last Decade and Down 68% Over the Last 5 Yearsi; Under the L

-- Studies highlight the clinical effectiveness of EXPAREL for total knee arthroplasty and long-term

Pacira BioSciences (NASDAQ:PCRX) sees FY2026 sales of $745.000 million-$770.000 million vs $790.214

Pacira BioSciences (NASDAQ:PCRX) reported quarterly earnings of $0.57 per share which missed the ana

-- LG Chem becomes exclusive distributor of EXPAREL -- – Partnership expands patient access to opioi

HC Wainwright & Co. analyst Douglas Tsao reiterates Pacira BioSciences (NASDAQ:PCRX) with a B

Needham analyst Serge Belanger maintains Pacira BioSciences (NASDAQ:PCRX) with a Buy and maintain

Barclays analyst Glen Santangelo initiates coverage on Pacira BioSciences (NASDAQ:PCRX) with a Eq

-- New data published in Pain Physician shows significant improvement in functional outcomes with io

Pacira BioSciences, Inc. (NASDAQ:PCRX), the industry leader in its commitment to deliver innovative,

HC Wainwright & Co. analyst Douglas Tsao assumes Pacira BioSciences (NASDAQ:PCRX) with a Buy

Truist Securities analyst Les Sulewski maintains Pacira BioSciences (NASDAQ:PCRX) with a Buy and

Pacira BioSciences (NASDAQ:PCRX) lowers FY2025 sales outlook from $730.000 million-$750.000 million

Pacira BioSciences (NASDAQ:PCRX) reported quarterly earnings of $0.70 per share which beat the analy

Pacira BioSciences, Inc. (NASDAQ: PCRX), the industry leader in its commitment to deliver innovative

Pacira BioSciences, Inc. (NASDAQ:PCRX), the industry leader in its commitment to deliver innovative,

-- Findings Presented at AMCP Nexus 2025 Annual Meeting --BRISBANE, Calif., Oct. 23, 2025 (GLOBE NEW

Pacira BioSciences, Inc. (NASDAQ:PCRX), the industry leader in its commitment to deliver innovative,

Pacira BioSciences (NASDAQ:PCRX) narrows FY2025 sales outlook from $725.000 million-$765.000 million

Pacira BioSciences (NASDAQ:PCRX) reported quarterly earnings of $0.74 per share which beat the analy

Partnership expected to advance 5x30 strategy by increasing ZILRETTA sales calls and extensively exp